GE HealthCare Secures $110 Target Following Strong Q3 Results

Argus Research recently increased its price target for GE HealthCare Technologies Inc. to $110.00 from $85.00, an adjustment of 29.41%, while maintaining a Buy rating led by analyst David Toung. GuruFocus recently reported the company trades at $83.15, compared to its GF Value estimate of $85.90. The stock carries a market capitalization of approximately $37.6 billion and a trailing twelve months price-to-earnings ratio of 17.57x, slightly beneath its five-year median of 18.5x.

The target increase followed third-quarter financial results in which GE HealthCare surpassed Wall Street targets. Third-quarter adjusted earnings came in at $1.34 per share, topping the Zacks Consensus Estimate of $1.21. Revenue reached $5.51 billion, above the forecasted $5.36 billion. Adjusted EBIT margin rose 180 basis points year over year to 16.6%, while the company's backlog grew 12% to $23.7 billion with a book-to-bill ratio of 1.03 times.

Following the third-quarter execution, Chief Financial Officer William Grogan announced higher full-year targets for 2026. The company adjusted its expected adjusted earnings to $4.95-$5.05 per share, up from the previous range of $4.80-$5.00. Organic revenue growth is now projected at approximately 4%, compared to the earlier 3%-4% forecast. GE HealthCare also raised its adjusted EBIT margin target to 15.5%-15.7% and projected free cash flow over $1.6 billion.

Executive leadership reported that hospital capital spending remains stable. Chief Executive Officer Peter Arduini stated that equipment installations are scheduled far ahead and that customer opportunities stay resilient. He highlighted Pharmaceutical Diagnostics as a key growth driver, noting that the unit achieved 13.8% organic revenue growth due to demand for contrast media and radiopharmaceuticals. Although fourth-quarter organic expansion is expected at 3%-4%, Grogan cited challenging prior-year comparisons in Patient Care Solutions rather than soft customer demand.

Management and investors continue to monitor several potential operational headwinds. Grogan noted that supply-chain inflation and higher memory chip prices partially offset productivity gains. Looking forward, Arduini pointed to potential Section 232 tariffs as an element of uncertainty for 2027, though leadership expects pricing adjustments and supplier initiatives will help counter ongoing inflationary pressures.